Evidence map›Paper›PMID 28716817›Full record

ArticleMolecular cancer therapeutics2017

PI3Kγ/δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature.

Evgeni Efimenko, Utpal P Davé, Irina V Lebedeva, Yao Shen, Maria J Sanchez-Quintero, Daniel Diolaiti, Andrew Kung, Brian J Lannutti, Jianchung Chen, Ronald Realubit and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. [The role and research progress of NOTCH1 in T-cell acute lymphoblastic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021
    Article
  6. Review
  7. Relapsed T Cell ALL: Current Approaches and New Directions.Current hematologic malignancy reports · 2019
    Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Evgeni EfimenkoDepartment of Pediatrics, Columbia University Medical Center, New York, New York.
Utpal P DavéDivision of Hematology/Oncology, Indiana University School of Medicine and the IU Simon Cancer Center, Indianapolis, Indiana.
Irina V LebedevaDepartment of Pediatrics, Columbia University Medical Center, New York, New York.
Yao ShenDepartment of Systems Biology, Columbia University, New York, New York.
Maria J Sanchez-QuinteroDepartment of Neurology, Columbia University Medical Center, New York, New York.
Daniel DiolaitiDepartment of Pediatrics, Columbia University Medical Center, New York, New York.
Andrew KungDepartment of Pediatrics, Columbia University Medical Center, New York, New York.
Brian J LannuttiOncternal Therapeutics. San Diego, California.
Jianchung ChenDepartment of Pediatrics, Columbia University Medical Center, New York, New York.
Ronald RealubitDepartment of Systems Biology, Columbia University, New York, New York.
Zoya NiatsetskayaDepartment of Pediatrics, Columbia University Medical Center, New York, New York.
Vadim TenDepartment of Pediatrics, Columbia University Medical Center, New York, New York.
Charles KaranDepartment of Systems Biology, Columbia University, New York, New York.
Xi ChenDepartment of Public Health Sciences, University of Miami, Miami Florida.
Andrea CalifanoDepartment of Systems Biology, Columbia University, New York, New York.
Thomas G DiacovoDepartment of Pediatrics, Columbia University Medical Center, New York, New York. td2142@cumc.columbia.edu.
Columbia University Irving Medical Center · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
High-performance compute cluster for biomedical computingS10OD012351 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2012 to 2012
$2.0M
The Role of LMO2 in the Pathogenesis of T-cell LeukemiaR01CA207530 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI DAVE, UTPAL P · 2016 to 2020
$1.8M
Targeting non-classical oncogenes as therapy for T-ALLR01CA169162 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI DIACOVO, THOMAS G · 2012 to 2016
$1.6M
Storage System for High Performance ComputingS10OD021764 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2016 to 2016
$600k
Pathophysiology of Adult T-cell Leukemia/LymphomaI01BX001799 · VA · VETERANS HEALTH ADMINISTRATION · PI DAVE, UTPAL P · 2013 to 2025
–
BLRD VA I01 BX001799NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA169162NCI NIH HHS R01 CA207530NIH HHS S10 OD012351NIH HHS S10 OD021764
6 · The paper itself

Abstract

PI3K/AKT and NOTCH1 signaling pathways are frequently dysregulated in T-cell acute lymphoblastic leukemias (T-ALL). Although we have shown that the combined activities of the class I PI3K isoforms p110γ and p110δ play a major role in the development and progression of PTEN-null T-ALL, it has yet to be determined whether their contribution to leukemogenic programing is unique from that associated with NOTCH1 activation. Using an

Indexed as

AnimalsCell Line, TumorCell ProliferationCell Transformation, NeoplasticClass Ib Phosphatidylinositol 3-KinaseClass I Phosphatidylinositol 3-KinasesGene Expression Regulation, LeukemicHumansMiceMutationPrecursor T-Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene Proteins c-mycReceptor, Notch1Signal TransductionClass Ib Phosphatidylinositol 3-KinaseClass I Phosphatidylinositol 3-KinasesMYC protein, humanNOTCH1 protein, humanPIK3CD protein, humanPIK3CG protein, humanProto-Oncogene Proteins c-mycReceptor, Notch1

Identifiers

PMID28716817
PMCPMC6075817
OpenAlexW2735125993

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.